{"result": "(\"entity\"<|>SIADH<|>EVENT<|>Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is a condition characterized by excessive release of antidiuretic hormone leading to hyponatremia in patients.)\n##\n(\"entity\"<|>ELLISON DH<|>PERSON<|>Ellison DH is a researcher who contributed to the diagnostic criteria for SIADH, as referenced in the New England Journal of Medicine.)\n##\n(\"entity\"<|>VERBALIS ET AL.<|>PERSON<|>Verbalis et al. are researchers who provided insights into the main causes of SIADH, as referenced in The American Journal of Medicine.)\n##\n(\"entity\"<|>NUTRICIÓN ARTIFICIAL<|>EVENT<|>Artificial nutrition refers to the provision of nutrients through means other than oral intake, often used in patients unable to eat normally.)\n##\n(\"entity\"<|>ACV<|>EVENT<|>Accidente cerebrovascular (ACV) refers to a stroke, which can be a cause of SIADH as mentioned in the text.)\n##\n(\"entity\"<|>HORMONA ANTIDIURÉTICA<|>EVENT<|>Antidiuretic hormone (ADH) is a hormone that helps regulate water balance in the body and is involved in the pathophysiology of SIADH.)\n##\n(\"entity\"<|>TUMORES<|>EVENT<|>Tumors can be a cause of SIADH, particularly pulmonary and non-thoracic tumors as listed in the text.)\n##\n(\"entity\"<|>ENFERMEDADES PULMONARES<|>EVENT<|>Pulmonary diseases can lead to SIADH, including infections and mechanical ventilation issues.)\n##\n(\"entity\"<|>SÍNDROME DE INMUNODEFICIENCIA ADQUIRIDA<|>EVENT<|>Acquired Immunodeficiency Syndrome (AIDS) is mentioned as a potential cause of SIADH.)\n##\n(\"relationship\"<|>ELLISON DH<|>SIADH<|>Ellison DH contributed to the diagnostic criteria for SIADH, providing essential insights into its diagnosis<|>8)\n##\n(\"relationship\"<|>VERBALIS ET AL.<|>SIADH<|>Verbalis et al. provided information on the main causes of SIADH, contributing to the understanding of the condition<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN ARTIFICIAL<|>SIADH<|>Artificial nutrition can influence the development of hyponatremia in patients, particularly in the context of SIADH<|>6)\n##\n(\"relationship\"<|>ACV<|>SIADH<|>ACV is listed as a potential cause of SIADH, indicating a relationship between the two<|>5)\n##\n(\"relationship\"<|>HORMONA ANTIDIURÉTICA<|>SIADH<|>ADH is central to the pathophysiology of SIADH, as its inappropriate secretion leads to the condition<|>9)\n##\n(\"relationship\"<|>TUMORES<|>SIADH<|>Certain tumors are known to cause SIADH, establishing a direct relationship<|>7)\n##\n(\"relationship\"<|>ENFERMEDADES PULMONARES<|>SIADH<|>Pulmonary diseases can lead to the development of SIADH, indicating a clear relationship<|>6)\n##\n(\"relationship\"<|>SÍNDROME DE INMUNODEFICIENCIA ADQUIRIDA<|>SIADH<|>AIDS is mentioned as a potential cause of SIADH, establishing a relationship<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: de pacientes con NP e hiponatremia, se objetivó hiponatremia euvolémica en el 75% pacientes (2/3 fueron diagnosticados de SIADH y el resto de elevación fisiológica de la ADH por dolor)61. Otras causas de hiponatremia euvolémica como la intoxicación aguda de agua, la polidipsia primaria y el déficit de sal, son infrecuentes en pacientes con NP. Respecto al déficit de sal, en este grupo de pacientes se ha encontrado un desarrollo de hiponatremia independiente del bajo aporte de sodio62. En ausencia de pérdidas corporales de sodio o una elevación no osmótica de la ADH, un paciente con bajo aporte de sal solo desarrolla hiponatremia si no dispone del suficiente soluto en la médula renal para eliminar todo el líquido aportado24. Esta última situación es\n\n| Tabla 2. Criterios esenciales para el diagnóstico del SIADH. Adaptada de Ellison DH et al. New England J Med, 2007. |\n|-------------------------------------------------------------------------------------------------------------------|\n| · Osm plasmática < 275 mOsmol/kg                                                                                   |\n| · OsmU inapropiada para la hiposmolalidad plasmática (OsmU > 100 mOsm/kg)                                          |\n| · Euvolemia clínica                                                                                                |\n| · NaU > 40 mmol/l, en presencia de una ingesta suficiente de sal                                                   |\n| · No uso reciente de diuréticos                                                                                    |\n| · Ausencia de insuficiencia suprarrenal secundaria e hipotiroidismo severo                                         |\n\nNaU (sodio urinario); Osm: osmolalidad; OsmU: osmolalidad urinaria.\n---\n806      BLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\nTabla 3. Principales causas del SIADH. Adaptada de Verbalis et al. The American Journal of Medicine 2013\n\n| Tumores |\n|----------|\n| Pulmonar/mediastino (ca de pulmón, mesotelioma, timoma) |\n| No-torácico (ca duodenal, ca pancreático, ca urotelial/próstata, ca uterino, ca nasofaríngeo, leucemia, linfoma y timoma) |\n\n| Trastornos del sistema nervioso central |\n|------------------------------------------|\n| Lesión ocupante de espacio (tumor, absceso cerebral, hematoma subdural) |\n| Enfermedad inflamatoria (encefalitis, meningitis, lupus sistémico, porfiria aguda intermitente) |\n| Degenerativa/desmielinizante (Guillain-Barré, lesión medular, esclerosis múltiple) |\n| Mixta (HSA, TCE, psicosis aguda, delirium tremens, sección del tallo hipofisario, cirugía transesfenoidal, hidrocefalia, vasculitis, trombosis del seno cavernoso, ACV) |\n\n| Farmacológico |\n|----------------|\n| Estímulo de la secreción de ADH (fenotiazidas, antidepresivos tricíclicos) |\n| Pontenciación del efecto renal de la ADH o efecto directo (desmopresina, inhibidores de la síntesis de prostaglandinas) |\n| Efecto mixto o desconocido (IECA, carbamacepina y oxacarbacepina, clozapina, inhibidores de la recaptación de la serotonina, vincristina) |\n\n| Enfermedades pulmonares |\n|--------------------------|\n| Infecciones (tuberculosis, neumonía, aspergilosis, empiema, bronquiectasias) |\n| Mecánico/ventilatorio (insuficiencia respiratoria aguda, EPOC, respiración mecánica) |\n\n| Otros |\n|--------|\n| Síndrome de inmunodeficiencia adquirida, arteritis de células gigantes, atrofia senil, idiopático |\n\nACV: accidente cerebrovascular; ADH: hormona antidiurética; Ca: carcinoma; EPOC: enfermedad obstructiva crónica; HSA: hemorragia subaracnoidea; IECA: inhibidores del sistema renina angiotensina aldosterona; TCE: traumatismo craneoencefálico.\n\ninfrecuente en los pacientes con NP, con el aporte de proteínas que reciben, se generan los suficientes osmo-les como para eliminar todo el líquido aportado.\n\nFinalmente, en la tabla 4 se resume el diagnóstico diferencial de la causa de hiponatremia en pacientes con nutrición artificial.\n\n## 5. Tratamiento de la hiponatremia en nutrición artificial\n\nEl objetivo del tratamiento de la hiponatremia varía en función de la gravedad neurológica de la misma. En pacientes con hiponatremia grave (disminución del ni-vel de conciencia, confusión, convulsiones, etc.) el prin-cipal objetivo es revertir la clínica neurológica del pa-ciente39\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}